{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:32:07Z","timestamp":1794047527384,"version":"4.8.0"},"reference-count":14,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"4","license":[{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"DOI":"10.3324\/haematol.2025.289085","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T08:57:55Z","timestamp":1765443475000},"page":"1500-1504","source":"Crossref","is-referenced-by-count":1,"title":["Combined asciminib and olverembatinib in blast-phase chronic myeloid leukemia"],"prefix":"10.3324","volume":"111","author":[{"given":"Fang","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"key":"88369","doi-asserted-by":"crossref","unstructured":"Senapati J, Jabbour E, Kantarjian H, Short NJ. Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia. Leukemia. 2023; 37(1):5-17.","DOI":"10.1038\/s41375-022-01736-5"},{"key":"88370","doi-asserted-by":"crossref","unstructured":"Atallah E, Deininger M. Advanced-stage chronic myeloid leukemia: options for difficult treatment situations. Drugs. 2025; 85(1):41-50.","DOI":"10.1007\/s40265-024-02108-2"},{"key":"88371","doi-asserted-by":"crossref","unstructured":"Brioli A, Lomaia E, Fabisch C. Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry. Leukemia. 2024; 38(5):1072-1080.","DOI":"10.1038\/s41375-024-02204-y"},{"key":"88372","doi-asserted-by":"crossref","unstructured":"Jabbour E, Oehler VG, Koller PB. Olverembatinib after failure of tyrosine kinase inhibitors, including ponatinib or asciminib: a phase 1b randomized clinical trial. JAMA Oncol. 2025; 11(1):28-35.","DOI":"10.1001\/jamaoncol.2024.5157"},{"key":"88373","doi-asserted-by":"crossref","unstructured":"Jiang Q, Li Z, Qin Y. Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1\/2 trial. J Hematol Oncol. 2022; 15(1):113.","DOI":"10.1186\/s13045-022-01334-z"},{"key":"88374","doi-asserted-by":"crossref","unstructured":"Kantarjian H, Zhai Y, Oehler VG. Olverembatinib in chronic myeloid leukemia-Review of historical development, current status, and future research. Cancer. 2025; 131(8):e35832.","DOI":"10.1002\/cncr.35832"},{"key":"88375","doi-asserted-by":"crossref","unstructured":"Curik N, Laznicka A, Polivkova V. Combination therapies with ponatinib and asciminib in a preclinical model of chronic myeloid leukemia blast crisis with compound mutations. Leukemia. 2024; 38(6):1415-1418.","DOI":"10.1038\/s41375-024-02248-0"},{"key":"88376","doi-asserted-by":"crossref","unstructured":"Wang G, Lv J, Tang C. Abstract 1463: ATP-site inhibitor olverembatinib, HQP1351, enhanced the effect of allosteric inhibitor on the resistance conferred by the compound mutations of BCR-ABL. Cancer Res. 2021; 81(13_Suppl):1463.","DOI":"10.1158\/1538-7445.AM2021-1463"},{"key":"88377","doi-asserted-by":"crossref","unstructured":"Jiang Q, Weiming L, Zhang Y. Safety and efficacy of Tgrx-678, a potent BCR::ABL1 allosteric inhibitor, in patients with tyrosine kinase inhibitor resistant and\/or intolerant chronic myeloid leukemia: updated results of phase 1 study Tgrx-678-1001. Blood. 2024; 144(Suppl 1):477.","DOI":"10.1182\/blood-2024-205300"},{"key":"88378","doi-asserted-by":"crossref","unstructured":"Hochhaus A, Baccarani M, Silver RT. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020; 34(4):966-984.","DOI":"10.1038\/s41375-020-0776-2"},{"key":"88379","doi-asserted-by":"crossref","unstructured":"Eide CA, Brewer D, Xie T. Overcoming clinical BCR-ABL1 compound mutant resistance with combined ponatinib and asciminib therapy. Cancer Cell. 2024; 42(9):1486-1488.","DOI":"10.1016\/j.ccell.2024.08.004"},{"key":"88380","doi-asserted-by":"crossref","unstructured":"Hall KH, Brooks A, Waller EK. Overcoming TKI resistance in a patient with chronic myeloid leukemia using combination BCR-ABL inhibition with asciminib and bosutinib. Am J Hematol. 2021; 96(8):E293-E295.","DOI":"10.1002\/ajh.26231"},{"key":"88381","doi-asserted-by":"crossref","unstructured":"Cortes JE, Lang F, Rea D. Asciminib in combination with imatinib, nilotinib, or dasatinib in patients with chronic myeloid leukemia in chronic or accelerated phase: phase 1 study final results. Leukemia. 2025; 39(5):1124-1134.","DOI":"10.1038\/s41375-025-02592-9"},{"key":"88382","doi-asserted-by":"crossref","unstructured":"Hughes TP, Saglio G, Geissler J. Asciminib add-on to imatinib demonstrates sustained high rates of ongoing therapy and deep molecular responses with prolonged follow-up in the ASC4MORE study. J Hematol Oncol. 2024; 17(1):12.","DOI":"10.1186\/s13045-024-01642-6"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/13045\/79192","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/13045\/79893","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/13045\/79192","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:10:36Z","timestamp":1794046236000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/13045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":14,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2025.289085","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,11]]}}}